Bcl-2 Antibody

Immunoreactive BCL2 protein was detected in the neoplastic cells of almost all follicular lymphomas whereas no BCL2 protein was detected in follicles affected by nonneoplastic processes or in normal lymphoid tissue. Every tumor with molecular-genetic evidence of t(14;18) translocation expressed detectable levels of the protein, regardless of whether the breakpoint was located in or at a distance from the gene. Overexpression blocks the apoptotic death of a pro-B-lymphocyte cell line.